ArticleInternational journal of cardiology2021
Five-year mortality and readmission rates in patients with heart failure in India: Results from the Trivandrum heart failure registry.
Article in International journal of cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 55 citations in OpenAlex.
- The Future of Cardiac Care: A Review on the Role for Non-Invasive, Home-Based Monitoring and Rehabilitation after Hospitalisation for Acute Decompensated Heart Failure.Current heart failure reports · 2026Review
- Scale of unmet solid organ transplantation need in India: a projection for organ transplant need by 2040.The Lancet regional health. Southeast Asia · 2026Article
- Review
- Study Design and Baseline Characteristics of the VERINA Study: Phase IV Evidence of Vericiguat for Worsening Heart Failure Management.Cardiology and therapy · 2026Article
- Understanding Roadblocks to Heart Failure Care (UNLOCK-HF): A Convergent Parallel Mixed-Methods Study in Kerala.Tropical medicine & international health : TM & IH · 2026Article
- Enhancing Guideline-Directed Medical Therapy at Discharge Through Collaborative Care: Evidence from the TIME-HF Cluster Randomized Controlled Trial.Wellcome open research · 2026Article
- Article
- Do gender differences matter in Acute Heart Failure? Insights from Indian College of Cardiology - National Heart Failure Registry, India.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Review
- Article
- One-year mortality and re-admission rate by disease etiology in National Heart Failure Registry of India.Nature communications · 2025Article
- Patterns of use and dose optimization of renin-angiotensin system modulators among chronic heart failure patients with reduced ejection fraction in resource-limited settings: a multicenter cohort study.Therapeutic advances in chronic disease · 2025Article
- Review
- Epidemiology and Burden of Heart Failure in Asia.JACC. Asia · 2024Review
- Exploring the Need and Benefits of Digital Therapeutics (DTx) for the Management of Heart Failure in India.Cureus · 2023Review
- Development and validation of heart failure-specific quality-of-life measurement tool in India.American heart journal plus : cardiology research and practice · 2023Article
- Heart Failure and Multimorbidity in Asia.Current heart failure reports · 2023Review
- Expert Consensus on Ivabradine-based Therapy for Heart Rate Management in Chronic Coronary Syndrome and Heart Failure with Reduced Ejection Fraction in India.Current cardiology reviews · 2023Article
- Clinical profile and 90 day outcomes of 10 851 heart failure patients across India: National Heart Failure Registry.ESC heart failure · 2022Article
- Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 7 institutions in 3 countries.
Funding
Abstract
introductionHeart failure (HF) has emerged as an important and increasing disease burden in India. We present the 5-year outcomes of patients hospitalized for HF in India.
methodsThe Trivandrum Heart Failure Registry (THFR) recruited consecutive patients admitted for acute HF among 16 hospitals in Trivandrum, Kerala in 2013. Guideline-directed medical therapy (GDMT) was defined as the combination of beta-blockers (BB), renin angiotensin system blockers (RAS), and mineralocorticoid receptor antagonists (MRA) in patients with HF with reduced ejection fraction (HFrEF, EF < 40%) at discharge. We used Cox proportional hazards models and Kaplan-Meier survival plots for analysis. The MAGGIC risk score variables were included as exposure variables.
resultsAmong 1205 patients [69% male, mean (SD) age = 61.2 (13.7) years], HFrEF constituted 62% of patients and among them, 25% received GDMT. The 5-year mortality rate was 59% (n = 709 deaths), and median survival was 3.1 years. Sudden cardiac death and pump failure caused 46% and 49% of the deaths, respectively. In the multivariate Cox model, components of GDMT associated with lower 5-year mortality risks were discharge prescription of BB, RAS blocker, and MRA. Older age, lower systolic blood pressure, NYHA class III or IV, and higher serum creatinine were also associated with higher 5-year mortality.
conclusionsThree out of every 5 patients had died during 5-years of follow-up with a median survival of approximately 3 years. Lack of GDMT in patients with HFrEF and frequent readmissions were associated with higher 5-year mortality. Quality improvement programmes with strategies to improve adherence to GDMT and reduction in readmissions may improve HF outcomes in this region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.